Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bio Light Israeli Life Sciences Investments Ltd announces start of clinical study with DiagnosTear Dry Eye Syndrome Diagnostic Assay


Monday, 10 Feb 2014 09:09am EST 

Bio Light Israeli Life Sciences Investments Ltd:Says DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.Says DiagnosTear is part of BioLight's XLVision Sciences ophthalmology cluster.Says the purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears of healthy subjects as well as patients with Dry Eye Syndrome.Says DiagnosTear is preparing to add another center in Israel to the clinical study soon and expects to report its results in the fourth quarter of 2014. 

Company Quote